Overview

Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, open-label, multicenter trial to evaluate the efficacy and safety of BN101 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least First Line of systemic therapy.
Phase:
Phase 2
Details
Lead Sponsor:
BioNova Pharmaceuticals (Shanghai) LTD.